Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Alimentary Pharmacol...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Alimentary Pharmacology & Therapeutics
Article
Data sources: UnpayWall
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Alimentary Pharmacology & Therapeutics
Article . 2021 . Peer-reviewed
License: Wiley Online Library User Agreement
Data sources: Crossref
Alimentary Pharmacology & Therapeutics
Other literature type . 2021
Data sources: Europe PubMed Central
Alimentary Pharmacology & Therapeutics
Article
Data sources: Microsoft Academic Graph
 View all 2 versions
Claim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 23 Aug 2021 English Publisher:WileyJournal:Alimentary Pharmacology & Therapeutics, volume 54, pages 848-849 (issn: 0269-2813, eissn: 1365-2036, Copyright policy )
Authors: Isabella Visuri; Carl Eriksson; Ola Olén; Yang Cao; Emelie Mårdberg; Olof Grip; Anders Gustavsson; +6 Authors

doi: 10.1111/apt.16569

pmid: 34425010

Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply

Abstract

LINKED CONTENTThis article is linked to Visuri et al and Haydek & Scott papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16555

Related Organizations
Keywords

Crohn Disease, Adalimumab, Antibodies, Monoclonal, Humans, Tumor Necrosis Factor Inhibitors, Infliximab

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
bronze
Related to Research communities
UArctic